AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
April 01 2021 - 9:00AM
Business Wire
Expanded collaboration includes an eight-target
discovery partnership leveraging AbCellera’s entire technology
stack, including the Trianni Mouse® and the OrthoMabTM bispecific
platforms
AbCellera (Nasdaq: ABCL) today announced agreements to expand
its collaboration with Gilead Sciences, Inc. (Gilead) including a
multi-year, multi-target antibody discovery collaboration and
access to AbCellera’s humanized mouse technology, the Trianni
Mouse®. Under the financial terms of the agreements, AbCellera will
receive an upfront payment and is eligible for milestone payments
and royalties based on the development and commercialization of
antibodies generated by AbCellera under this collaboration.
Building on the successful completion of the first collaboration
together, under the new agreement AbCellera will generate panels of
antibodies for up to eight new targets, across multiple
indications, selected by Gilead. The expanded collaboration will
leverage the full breadth of AbCellera’s technology stack,
including the recently added capabilities for sourcing diverse,
fully-humanized antibodies using the Trianni Mouse® platform and
combining any two antibodies to create native bispecifics using the
OrthoMabTM protein engineering platform.
“We are excited to build on the success of the first program and
deepen our relationship with the team at Gilead,” said Carl Hansen,
Ph.D., CEO and President of AbCellera. “We are particularly pleased
to see the value created for our partners by quickly integrating
the Trianni Mouse® and OrthoMabTM platforms, which we acquired in
second half of 2020.”
AbCellera’s partners benefit from an operating system designed
to support many antibody modalities, unlock new targets, and
increase the speed and the probability of success of their
therapeutic antibody discovery programs. AbCellera’s AI-powered
technology stack brings together microfluidics, single cell
analysis, machine learning, computation, custom robotics, and
automation to compound the power of each step in the discovery
process.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, visit www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s beliefs and
assumptions and on information currently available to management.
All statements contained in this release other than statements of
historical fact are forward-looking statements, including
statements regarding our ability to develop, commercialize and
achieve market acceptance of our current and planned products and
services, our research and development efforts, and other matters
regarding our business strategies, use of capital, results of
operations and financial position, and plans and objectives for
future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210401005237/en/
Inquiries Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236)521-6774 Business Development:
Kevin Heyries, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor
Relations: Melanie Solomon; ir@abcellera.com,
+1(778)729-9116
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Sep 2023 to Sep 2024